Klayon Therapeutics
Zwitterionic peptide-based radiopharmaceutical platform for precise tumor targeting
healthcare / radiopharmaceuticals / oncology
Founded2025
Employees2
LocationCarmel, IN
Business modelB2B / partnerships / collaborations
About
Klayon Therapeutics develops radiopharmaceuticals using the Z-ION ARK™ platform, a zwitterionic peptide-based technology designed to reduce non-specific binding and improve tumor targeting in oncology. The platform forms hydration barriers to limit protein binding, enhance pharmacokinetics, and support broad isotope and ligand compatibility. Klayon collaborates with pharmaceutical companies, academic institutions, and investors to advance radiopharmaceutical development.
Product
- Value proposition
- Z-ION ARK™, a zwitterionic peptide platform that reduces non-specific binding to improve safety, pharmacokinetics, and tumor targeting of radiopharmaceuticals.
- Target customers
- pharmaceutical companies, academic institutions, investors
Founders
- Jaden Hyungseok C. (CEO & Founder)
- Sunghoon Lee (General Director)
Categories
RadiopharmaceuticalsOncologyBiotech startup
Products
Z-ION ARK™ platformZ-ION ARK™-based radiopharmaceuticals (ligand-agnostic platform)
Key features
reduces non-specific bindingforms hydration layers to limit protein bindingcharge-balanced zwitterionic peptidesimproves circulation and pharmacokineticsbroad isotope and ligand compatibility
Technologies
Z-ION ARK™ zwitterionic peptide engineeringradiopharmaceutical platformpharmacokinetic optimization
Integrations
various radiopharmaceutical ligandsdiverse isotopes
Target conditions
canceroncology indications
Care settings
clinical developmentlaboratory researchhospital/academic collaboration
Certifications
SOC
Partnerships
co-development and platform integration opportunities with ligand librariesjoint research and translational studiesinvestment partnerships
News
- Daejeon Technopark opens global biotech gateway · 2026-04-28T00:00:00.000Z
- Antibiotic resistance: a digital platform to choose the most effective therapy - Kelyon · 2025-07-16T09:40:50.000Z
- K2B Therapeutics | Re-writing the Rules of Targeted Cancer Therapy · 2025-02-21T21:29:36.000Z
- Kinoxis Therapeutics - Social Neuroscience Guided Therapeutics · 2025-05-28T14:49:41.000Z
- Cellogen Therapeutics Raises Rs 20 Crore to Accelerate Affordable CAR-T Cancer Therapy in India - LaunchX Media · 2026-05-19T08:37:57.000Z
Browse similar startups
Related startups
- MSK Masters — Sunman, IN
- Navigate Maternity — Fort Wayne, IN
- Predictive Wear — West Lafayette, IN
- Sugar Grove Senior Living, LLC — Plainfield, IN
- Adipo Therapeutics — Indianapolis, IN
- Curiva — South Bend, IN
- KNOWN — chicago, IL
- Krystal Vision Eye Care — Philadelphia, PA
- LearnYour Benefits — Plymouth, MN
- Lehigh Valley Oral Surgery and Implant Center — Bethlehem, PA
- LENTECHS — Columbus, OH
- Liberate Bio — Boston, MA
Profile updated Jul 29, 2026. Sources: klayontherapeutics.com
